Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?
J Thorac Dis
.
2018 Jul;10(Suppl 18):S2130-S2132.
doi: 10.21037/jtd.2018.06.45.
Authors
Anthonie J van der Wekken
1
,
Klaas Kok
2
,
Harry J M Groen
1
Affiliations
1
Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
2
Department of Genetics, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
PMID:
30123541
PMCID:
PMC6072953
DOI:
10.21037/jtd.2018.06.45
No abstract available
Publication types
Editorial
Comment